Printer Friendly

BRISTOL-MYERS SQUIBB FILES SHELF REGISTRATION STATEMENT WITH SEC

 NEW YORK, May 11 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today the filing of a shelf registration statement with the Securities and Exchange Commission under which the company could issue up to $1 billion of debt securities.
 The company said it may offer securities from time to time in amounts and on terms to be determined at the time of the sale.
 Proceeds from the sale of these securities will be used for general corporate purposes, including, without limitation, working capital, capital expenditures, stock purchase programs, repayment and refinancing of borrowings and acquisitions.
 Any offer of securities pursuant to the registration statement will be made only by means of a prospectus.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any State in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State.
 -0- 5/11/93
 /CONTACT: Anthony Carter of Bristol-Myers Squibb, 212-546-4339/
 (BMY)


CO: Bristol-Myers Squibb Company ST: New York IN: MTC SU:

SH -- NY083 -- 7185 05/11/93 15:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 11, 1993
Words:240
Previous Article:BELL CANADA ISSUES DEBENTURES IN THE EUROPEAN MARKET
Next Article:GENERAL SIGNAL AGREES TO SALE OF GCA'S INTEGRATED SOLUTIONS
Topics:


Related Articles
BRISTOL-MYERS SQUIBB FILES NDA WITH FDA TO MARKET TAXOL
BRISTOL-MYERS SQUIBB COMPANY ISSUES STATEMENT
BRISTOL-MYERS SQUIBB COMPANY WINS APPEAL ON BUSPAR(R) PATENT INFRINGEMENT LAWSUIT
BRISTOL-MYERS SQUIBB FILES CLAIMS AGAINST CANADIAN COMPANY FOR MISREPRESENTATION OF ANTICANCER PRODUCT
Bristol-Myers Squibb and Cubist Pharmaceuticals Announce First Milestone Payment in Potential $56 Million Collaboration For Anti-Infective Drugs
Bristol-Myers Squibb and Pharmacopeia Form Research Alliance in Immunology/Inflammation
Ascent Pediatrics to Market Bristol-Myers Squibb's Duricef (Cefadroxil Monohydrate, USP) Oral Suspension
Bristol-Myers Squibb Files Shelf Registration Statement With Securities and Exchange Commission
Motion Filed for Preliminary Injunction in PLAVIX(R) Patent Infringement Case.
Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters